Department of Regenerative and Cancer Cell Biology, Albany Medical Center, Albany, New York, USA.
Division of Nephrology and Hypertension, Vanderbilt Medical School, Nashville, Tennessee, USA.
FASEB J. 2018 May;32(5):2644-2657. doi: 10.1096/fj.201700722R. Epub 2018 Jan 3.
Although yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), nuclear transducers of the Hippo pathway, are mostly silent in adult organs, aberrant activation of YAP/TAZ promotes tumorigenesis and abnormal tissue repair. The extent of involvement of TAZ in chronic kidney disease (CKD) is unknown. In our study, increased TAZ nuclear accumulation and expression in the tubulointerstitium was readily evident in 3 models of renal injury including obstructive, aristolochic acid (AA), and diabetic nephropathy, correlating with fibrosis progression. Stable TAZ overexpression in human kidney (HK)-2 epithelial cells promoted connective tissue growth factor (CTGF), fibronectin, vimentin, and p21 expression, epithelial dedifferentiation, and growth inhibition, in part, via Sma mothers against decapentaplegic homologue (SMAD)-3-dependent CTGF induction. CTGF secretion by TAZ-overexpressing epithelium also triggered proliferative defects in nonengineered HK-2 cells confirming a nonautonomous role of TAZ ( via a paracrine mechanism) in orchestrating kidney epithelial cell-cell communication. Renal tubular-specific induction of TGF-β1 in mice and TGF-β1 stimulation of HK-2 cells resulted in TAZ protein up-regulation. TAZ stable silencing in HK-2 cells abrogated TGF-β1-induced expression of target genes without affecting SMAD3 phosphorylation, which is also crucial for fibrotic reprogramming. Thus, TAZ was activated in fibrosis through TGF-β1-dependent mechanisms and sustained TAZ signaling promotes epithelial maladaptive repair. TAZ is also a novel non-SMAD downstream effector of renal TGF-β1 signaling, establishing TAZ as a new antifibrosis target for treatment of CKD.-Anorga, S., Overstreet, J. M., Falke, L. L., Tang, J., Goldschmeding, R. G., Higgins, P. J., Samarakoon, R. Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype.
虽然 yes 相关蛋白 (YAP) 和转录共激活因子与 PDZ 结合基序 (TAZ) 是 Hippo 通路的核转导子,但在成人器官中它们大多处于沉默状态,YAP/TAZ 的异常激活促进了肿瘤发生和异常组织修复。TAZ 在慢性肾脏病 (CKD) 中的参与程度尚不清楚。在我们的研究中,在包括梗阻性、马兜铃酸 (AA) 和糖尿病肾病在内的 3 种肾损伤模型中,肾小管间质中 TAZ 的核积累和表达明显增加,与纤维化进展相关。人肾 (HK)-2 上皮细胞中 TAZ 的稳定过表达促进了结缔组织生长因子 (CTGF)、纤维连接蛋白、波形蛋白和 p21 的表达、上皮去分化和生长抑制,部分通过 Sma 母亲对抗 decapentaplegic 同源物 (SMAD)-3 依赖性 CTGF 诱导。TAZ 过表达上皮细胞分泌的 CTGF 也触发了非工程化 HK-2 细胞的增殖缺陷,证实了 TAZ(通过旁分泌机制)在协调肾脏上皮细胞-细胞通讯中的非自主性作用。在小鼠中肾小管特异性诱导 TGF-β1 和 TGF-β1 刺激 HK-2 细胞导致 TAZ 蛋白上调。HK-2 细胞中 TAZ 的稳定沉默消除了 TGF-β1 诱导的靶基因表达,而不影响 SMAD3 磷酸化,这对纤维化重编程也很重要。因此,TAZ 通过 TGF-β1 依赖性机制在纤维化中被激活,持续的 TAZ 信号促进上皮细胞适应性修复。TAZ 也是肾脏 TGF-β1 信号的一种新型非 SMAD 下游效应物,确立了 TAZ 作为治疗 CKD 的一种新的抗纤维化靶标。-Anorga, S., Overstreet, J. M., Falke, L. L., Tang, J., Goldschmeding, R. G., Higgins, P. J., Samarakoon, R. Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype.